

# Management and operation of pharmacovigilance system in EAEU. Critical aspects



*«Pharmacovigilance:  
more clarity –  
fewer difficulties!»*

Registration:

[info@smart-pharma.group](mailto:info@smart-pharma.group)

20-21 of February 2020  
Vilnius, Lithuania  
Margis Trakai Hotel

Who should attend:

- Manufacturers/MAHs of medicines on the territory of the EAEU
- QPPVs
- Directors / Managers / Drug Safety Specialists (Global / local)
- Medical Directors / Heads of Medical Departments
- Directors of Global Regulatory Affairs
- Regulatory Managers
- Specialist responsible for development of PV system documentation
- Heads of Clinical Research Departments
- Specialist responsible for development of clinical research documentation, PILs, SmPCs

Member of International Society ISOP. Participated in the development of the EAEU PV quality system, developed an original algorithms and documents within the framework of the quality system of the PV. Experienced pharmacovigilance expert fulfilling the responsibilities of QPPV of six companies on the territory of the EAEU and a LPPV of the foreign companies in the EAEU.

Qualification has been confirmed by numerous certificates and implemented in the successful development and operation of the pharmacovigilance system in the EAEU.

During the course you will learn about:

- peculiarities of mutual recognition procedure in the EAEU countries
- models of quality system (QS)
- quality system of pharmacovigilance system
- peculiarities of the PV QS and relevant responsibilities of MAH
- preparation of system's master file depending on the QS model
- critical processes and procedures of quality systems
- important features of development / improvement of pharmacovigilance procedures
- critical aspects of the pharmacovigilance system audit / inspection
- pharmacovigilance during clinical trials
- storage and archiving of pharmacovigilance information
- interaction with distributors as a part of PV QS operation

